This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Progestagen Type in Postmenopausal Hormone Therapy and Blood Gene Expression Profile (ProGEP)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2011 by University Hospital of North Norway.
Recruitment status was:  Active, not recruiting
Information provided by (Responsible Party):
University Hospital of North Norway Identifier:
First received: April 30, 2010
Last updated: November 2, 2011
Last verified: November 2011
The purpose of this study is to compare combined postmenopausal hormone therapy natural progesterone to the one containing synthetic progestagen (i.e. chlormadinone acetate) at the blood transcriptome level.

Condition Intervention Phase
Pharmacogenomics Systems Biology Drug: Progesterone Drug: Chlormadinone acetate Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: Progestagen Type in Postmenopausal Hormone Therapy and Blood Gene Expression

Resource links provided by NLM:

Further study details as provided by University Hospital of North Norway:

Primary Outcome Measures:
  • Whole blood and white blood cells gene expression profiling after 3 months of HT treatment [ Time Frame: 0 and 3 months after treatment ]

Secondary Outcome Measures:
  • Quality of life, proteome, plasma haemostatic variable measurements [ Time Frame: 0,3,6 and 12 months ]
  • Whole blood and white blood cells gene expression profiling after 12 months of HT treatment [ Time Frame: 0 and 12 months after treatment ]

Estimated Enrollment: 40
Study Start Date: December 2008
Estimated Study Completion Date: October 2012
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Natural progesterone
Combined menopausal treatment containing natural progesterone
Drug: Progesterone
200 mg/day oral micronized natural progesterone (e.g. Utrogestan® 100mg) + 0.05 mg/day transdermal (i.e. plaster) 17β-estradiol (e.g. Estraderm® 50µg) during a year
Active Comparator: Chlormadinone acetate
Combined menopausal treatment containing chlormadinone acetate
Drug: Chlormadinone acetate
5 mg/day oral chlormadinone acetate (e.g. Luteran® 5mg)+ 0.05 mg/day transdermal (i.e. plaster) 17β-estradiol (e.g. Estraderm® 50µg)


Ages Eligible for Study:   45 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Postmenopausal women defined as:

    • 45 years< age < 65 years
    • Amenorrhoeic for ≥ 1 year
    • Amenorrhoeic for < 1 year either without any withdrawal vaginal bleeding for 3 consecutive months in spite of a cyclic progestagen treatment and/or blood estradiol levels ≤ 20 pg/mL and blood FSH levels ≥ 40 UI/mL
    • Women with bilateral ovariectomy
  • Women suffering of at least 1 postmenopausal symptoms listed:

    • Hot flashes,
    • Memory and Concentration Problems,
    • Mood Swings,
    • Insomnia,
    • Urinary Incontinence,
    • Night sweating,
    • Join pains,
    • Asthenia.
  • No use of hormone therapy (HT)
  • Previous HT user:

    • HT use < 3 months - stop for 6 months
    • HT use <= 1 year - stop for > 12 months
  • If previous use of soya derivatives in dietary supplements: washout period = 3 months
  • Signed informed consent, after having received both oral- and written- information regarding the study goals, its risks and benefits and its constraints, including the 12 month follow-up. A delay should be respected between information and the signature of the written consent.

Exclusion Criteria:

  • Past HT users who have used treatment for more than 1 year
  • Hysterectomized women
  • Women without health insurance (only in French centre)
  • History of cardio-vascular accident either arterial or venous
  • Untreated high blood pressure
  • Liver disease
  • Diabetes
  • History of cancer except basal-cell skin cancer and colon cancer
  • Severe history of familial breast cancer defined as at least 2 women first degree- relatives with breast cancer diagnosis before 50 years
  • History of severe mastalgia
  • History of breast biopsy showing hyperplasia (with or without atypia)
  • Undiagnosed vaginal bleeding
  • Diagnosed endometrial hyperplasia
  • Auto-immune disease (e.g. lupus)
  • Women with kidney transplant
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01123538

Gynecology center, Helse Nord
Bodø, Norway
Sponsors and Collaborators
University Hospital of North Norway
Principal Investigator: Eiliv Lund, MD, PhD Institute of Community Medicine, Tromsø, Norway
Study Director: Vanessa Dumeaux, PharmD, PhD Institute of community medicine, Tromsø, Norway
  More Information

Responsible Party: University Hospital of North Norway Identifier: NCT01123538     History of Changes
Other Study ID Numbers: EudraCT-2006-004462-14
2006-004462-14 ( EudraCT Number )
Study First Received: April 30, 2010
Last Updated: November 2, 2011

Additional relevant MeSH terms:
Chlormadinone Acetate
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Androgen Antagonists
Hormone Antagonists
Contraceptives, Oral, Synthetic
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents processed this record on June 23, 2017